NLS Profiles

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the leap to go on your […]

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder of BioTie Therapies and Faron Pharmaceuticals. BioTie Therapies and Faron Pharmaceuticals develop drugs for inflammation and immune-related conditions. In 2016, BioTie was acquired by Acorda Therapeutics. How did you turn basic research findings into companies? “When we returned from […]

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Habib Frost, MD, could not get over the helplessness he felt as a young emergency medicine intern in Denmark seeing two young people die in the same day from cardiac arrest, despite having access to skilled providers and the latest technology.

Bernard L. Feringa is pioneer in the field of molecular engines and he strives to inspire his students, stimulate their creativity and help them appreciate the beauty of nature.